Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds investigator-initiated research and education to advance science in cystic fibrosis, pain, IgA nephropathy, beta thalassemia, and sickle cell disease.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (Cystic fibrosis, IgA nephropathy, Pain (US only), Grants, Sponsorships) | RFP window (Beta thalassemia & Sickle cell disease; currently closed)
Funding Amounts: No strict cap; budget must represent fair market value and not exceed 35% overhead. Typically, no more than 30% of an organization’s annual budget per year.
Summary: Supports investigator-initiated studies, grants, and sponsorships to advance research, education, and innovation in serious diseases such as cystic fibrosis, pain, and rare conditions.
Key Information: Proposals must align with Vertex’s disease areas of interest and comply with documentation and budget guidelines.
Description
Vertex Pharmaceuticals provides funding and/or product support for investigator-sponsored studies (ISS), independent research, grants, and sponsorships to advance scientific knowledge, patient education, and innovation in areas aligned with its research priorities. The primary focus is on serious diseases, especially cystic fibrosis, pain (US only), IgA nephropathy, beta thalassemia, and sickle cell disease. Funding is available for a range of research types, including clinical, observational, and nonclinical studies, as well as educational and advocacy initiatives.
Vertex also offers grants for independent medical education, patient advocacy, and organizational sponsorships. Proposals must demonstrate clear alignment with Vertex’s therapeutic interests and follow strict documentation and budget guidelines.
